ANEB
Anebulo Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.26
-0.02 (-5.45%)
Current Price
| Previous Close | $0.28 |
| Open | $0.87 |
| Day High | $0.87 |
| Day Low | $0.87 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 40.78M |
| Cash Equivalents | $9.04M |
| Net Income | $-7.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.60M |
| EPS (TTM) | $-0.19 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.56M |
| Income | $-7.98M |
| Book/sh | $0.19 |
| Cash/sh | $0.22 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 6.12 |
| Current Ratio | 6.24 |
Returns & Margins
| ROA | -45.04% |
| ROE | -69.69% |
Ownership
| Insider Ownership | 40.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.40 |
| P/B | 1.35 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.27 |
| SMA50 | $0.31 |
| SMA200 | $0.48 |
| RSI | 45.44 |
| ATR | 0.0684 |
| Shares Float | 24.13M |
| Short Float | 2.11% |
| Short Ratio | 1.65 |
| Volatility | -1.89 |
| Rel Volume | 0.54 |
Performance History
| Week | -11.86% |
| Month | -18.75% |
| Quarter | -21.21% |
| 6 Months | -46.17% |
| YTD | -76.99% |
| Year | -90.55% |
| 3 Years | -90.30% |
| 5 Years | -96.44% |
| 10 Years | -96.34% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $0.26 | 100 |
| 2026-10-26 | $0.28 | 100 |
| 2026-10-23 | $0.29 | 100 |
| 2026-10-22 | $0.29 | 100 |
| 2026-10-21 | $0.29 | 100 |
| 2026-10-20 | $0.29 | 100 |
| 2026-10-19 | $0.00 | 1,100 |
| 2026-10-16 | $0.00 | 800 |
| 2026-10-15 | $0.31 | 100 |
| 2026-10-14 | $0.31 | 100 |
| 2026-10-13 | $0.31 | 100 |
| 2026-10-12 | $0.31 | 100 |
| 2026-10-09 | $0.31 | 100 |
| 2026-10-08 | $0.31 | 100 |
| 2026-10-07 | $0.32 | 100 |
| 2026-10-06 | $0.32 | 100 |
| 2026-10-05 | $0.32 | 100 |
| 2026-10-02 | $0.32 | 100 |
| 2026-10-01 | $0.32 | 100 |
| 2026-09-30 | $0.32 | 100 |
| 2026-09-29 | $0.32 | 100 |
| 2026-09-28 | $0.32 | 100 |
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
đ° Latest News
No news articles available at the moment. Check back later for updates on ANEB.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $382,014 | $151,230 | $0 | $0 |
| Total Expenses | $8,359,467 | $8,308,755 | $11,783,599 | $6,831,174 |
| Other Income Expense | $-1,195 | $9,260 | $-41,146 | $-1,777 |
| Other Non Operating Income Expenses | $-1,195 | $9,260 | $-41,146 | $-1,777 |
| Net Non Operating Interest Income Expense | $-124,101 | $97,792 | $92,407 | $7,332 |
| Interest Expense Non Operating | $382,014 | $151,230 | $0 | $0 |
| Operating Expense | $8,359,467 | $8,308,755 | $11,783,599 | $6,831,174 |
| Other Operating Expenses | $-864,014 | - | - | - |
| General And Administrative Expense | $4,923,540 | $4,759,818 | $6,183,402 | $3,869,636 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Net Interest Income | $-124,101 | $97,792 | $92,407 | $7,332 |
| Interest Income | $257,913 | $249,022 | $92,407 | $7,332 |
| Normalized Income | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Net Income From Continuing And Discontinued Operation | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Total Operating Income As Reported | $-9,223,481 | $-8,308,755 | $-11,783,599 | $-6,831,174 |
| Net Income Common Stockholders | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Net Income | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Net Income Including Noncontrolling Interests | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Net Income Continuous Operations | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Pretax Income | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Interest Income Non Operating | $257,913 | $249,022 | $92,407 | $7,332 |
| Operating Income | $-8,359,467 | $-8,308,755 | $-11,783,599 | $-6,831,174 |
| Per Share | ||||
| Diluted EPS | $-0.25 | $-0.32 | $-0.47 | $-0.29 |
| Basic EPS | $-0.25 | $-0.32 | $-0.47 | $-0.29 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,102,749 | $-8,050,473 | $-11,732,338 | $-6,831,174 |
| EBITDA (Bullshit earnings) | $-8,102,749 | $-8,050,473 | $-11,732,338 | $-6,831,174 |
| EBIT | $-8,102,749 | $-8,050,473 | $-11,732,338 | $-6,831,174 |
| Diluted Average Shares | $33,820,306 | $25,822,258 | $25,074,481 | $23,344,567 |
| Basic Average Shares | $33,820,306 | $25,822,258 | $25,074,481 | $23,344,567 |
| Diluted NI Availto Com Stockholders | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Research And Development | $4,299,941 | $3,548,937 | $5,600,197 | $2,961,538 |
| Selling General And Administration | $4,923,540 | $4,759,818 | $6,183,402 | $3,869,636 |
| Other Gand A | $1,575,768 | $1,798,047 | $2,590,535 | $1,430,267 |
| Salaries And Wages | $3,347,772 | $2,961,771 | $3,592,867 | $2,439,369 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-03-02
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Total Assets | $12,145,616 | $4,073,114 | $11,670,151 | $15,579,431 |
| Total Non Current Assets | $183,110 | $565,124 | $0 | $0 |
| Other Non Current Assets | $183,110 | $565,124 | - | - |
| Current Assets | $11,962,506 | $3,507,990 | $11,670,151 | $15,579,431 |
| Prepaid Assets | $261,439 | $413,790 | $422,748 | $1,030,960 |
| Receivables | $73,218 | $0 | - | - |
| Other Receivables | $73,218 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $11,627,849 | $3,094,200 | $11,247,403 | $14,548,471 |
| Cash And Cash Equivalents | $11,627,849 | $3,094,200 | $11,247,403 | $14,548,471 |
| Cash Financial | - | - | $11,247,403 | $14,548,471 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $487,688 | $260,583 | $1,068,801 | $512,531 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $487,688 | $260,583 | $1,068,801 | $512,531 |
| Payables And Accrued Expenses | $487,688 | $260,583 | $1,068,801 | $512,531 |
| Payables | $224,175 | $156,426 | $534,545 | $380,828 |
| Accounts Payable | $224,175 | $156,426 | $534,545 | $380,828 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Total Equity Gross Minority Interest | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Stockholders Equity | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Retained Earnings | $-73,888,507 | $-65,403,744 | $-57,202,041 | $-45,469,703 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $41,084,731 | $25,933,217 | $25,633,217 | $23,344,567 |
| Share Issued | $41,084,731 | $25,933,217 | $25,633,217 | $23,344,567 |
| Tangible Book Value | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Invested Capital | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Working Capital | $11,474,818 | $3,247,407 | $10,601,350 | $15,066,900 |
| Total Capitalization | $11,657,928 | $3,812,531 | $10,601,350 | $15,066,900 |
| Additional Paid In Capital | $85,505,349 | $69,190,341 | $67,777,757 | $60,513,258 |
| Capital Stock | $41,086 | $25,934 | $25,634 | $23,345 |
| Common Stock | $41,086 | $25,934 | $25,634 | $23,345 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $263,513 | $104,157 | $534,256 | $131,703 |
| Duefrom Related Parties Current | - | - | - | - |
Fetched: 2026-03-02
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,349,687 | $-8,090,849 | $-9,683,133 | $-5,437,174 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,349,687 | $-8,090,849 | $-9,683,133 | $-5,437,174 |
| Cash Flow From Continuing Operating Activities | $-6,349,687 | $-8,090,849 | $-9,683,133 | $-5,437,174 |
| Operating Gains Losses | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $15,000,000 | $0 | $6,646,748 | $0 |
| Financing Cash Flow | $14,883,336 | $-62,354 | $6,382,065 | $0 |
| Cash Flow From Continuing Financing Activities | $14,883,336 | $-62,354 | $6,382,065 | $0 |
| Net Other Financing Charges | $-116,664 | $-62,354 | $-317,083 | - |
| Net Common Stock Issuance | $15,000,000 | $0 | $6,646,748 | $0 |
| Common Stock Issuance | $15,000,000 | $0 | $6,646,748 | $0 |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $11,627,849 | $3,094,200 | $11,247,403 | $14,548,471 |
| Beginning Cash Position | $3,094,200 | $11,247,403 | $14,548,471 | $19,985,645 |
| Changes In Cash | $8,533,649 | $-8,153,203 | $-3,301,068 | $-5,437,174 |
| Change In Working Capital | $306,238 | $-799,260 | $1,164,482 | $907,784 |
| Change In Payables And Accrued Expense | $227,105 | $-808,218 | $556,270 | $270,898 |
| Change In Accrued Expense | $159,356 | $-430,099 | $402,553 | $118 |
| Change In Payable | $67,749 | $-378,119 | $153,717 | $270,780 |
| Change In Account Payable | $67,749 | $-378,119 | $153,717 | $270,780 |
| Change In Prepaid Assets | $152,351 | $8,958 | $608,212 | $636,886 |
| Change In Receivables | $-73,218 | $0 | - | $0 |
| Other Non Cash Items | $382,014 | $151,230 | - | - |
| Stock Based Compensation | $1,446,824 | $758,884 | $884,723 | $480,661 |
| Net Income From Continuing Operations | $-8,484,763 | $-8,201,703 | $-11,732,338 | $-6,825,619 |
| Proceeds From Stock Option Exercised | - | $0 | $52,400 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Preferred Stock Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-03-02